These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25378522)

  • 21. Hepatitis C among people who inject drugs in Tbilisi, Georgia: an urgent need for prevention and treatment.
    Bouscaillou J; Champagnat J; Luhmann N; Avril E; Inaridze I; Miollany V; Labartkava K; Kirtadze I; Butsashvili M; Kamkamidze G; Pataut D
    Int J Drug Policy; 2014 Sep; 25(5):871-8. PubMed ID: 24529802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
    Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
    HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
    Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
    Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study.
    Vickerman P; Hickman M; Judd A
    Int J Epidemiol; 2007 Apr; 36(2):396-405. PubMed ID: 17218325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of chronic hepatitis C virus infection - Dutch national guidelines.
    de Bruijne J; Buster EH; Gelderblom HC; Brouwer JT; de Knegt RJ; van Erpecum KJ; Schalm SW; Bakker CM; Zaaijer HL; Janssen HL; Reesink HW;
    Neth J Med; 2008; 66(7):311-22. PubMed ID: 18663263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of deaths related to Hepatitis C and AIDS in Scotland.
    Palmateer NE; Hutchinson SJ; McLeod A; Codere G; Goldberg DJ
    J Viral Hepat; 2007 Dec; 14(12):870-4. PubMed ID: 18070290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevention and treatment of hepatitis C in illicit drug users].
    Sakoman S
    Acta Med Croatica; 2009 Dec; 63(5):437-42. PubMed ID: 20198904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HCV burden in Europe and the possible impact of current treatment.
    Mathurin P
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S314-7. PubMed ID: 24091109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand.
    Gane E; Stedman C; Brunton C; Radke S; Henderson C; Estes C; Razavi H
    N Z Med J; 2014 Dec; 127(1407):61-74. PubMed ID: 25530333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surveillance for acute viral hepatitis - United States, 2007.
    Daniels D; Grytdal S; Wasley A;
    MMWR Surveill Summ; 2009 May; 58(3):1-27. PubMed ID: 19478727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimates on HCV disease burden worldwide - filling the gaps.
    Wedemeyer H; Dore GJ; Ward JW
    J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies to manage hepatitis C virus (HCV) disease burden.
    Wedemeyer H; Duberg AS; Buti M; Rosenberg WM; Frankova S; Esmat G; Örmeci N; Van Vlierberghe H; Gschwantler M; Akarca U; Aleman S; Balık I; Berg T; Bihl F; Bilodeau M; Blasco AJ; Brandão Mello CE; Bruggmann P; Calinas F; Calleja JL; Cheinquer H; Christensen PB; Clausen M; Coelho HS; Cornberg M; Cramp ME; Dore GJ; Doss W; El-Sayed MH; Ergör G; Estes C; Falconer K; Félix J; Ferraz ML; Ferreira PR; García-Samaniego J; Gerstoft J; Giria JA; Gonçales FL; Guimarães Pessôa M; Hézode C; Hindman SJ; Hofer H; Husa P; Idilman R; Kåberg M; Kaita KD; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; Lázaro P; Marinho RT; Marotta P; Mauss S; Mendes Correa MC; Moreno C; Müllhaupt B; Myers RP; Nemecek V; Øvrehus AL; Parkes J; Peltekian KM; Ramji A; Razavi H; Reis N; Roberts SK; Roudot-Thoraval F; Ryder SD; Sarmento-Castro R; Sarrazin C; Semela D; Sherman M; Shiha GE; Sperl J; Stärkel P; Stauber RE; Thompson AJ; Urbanek P; Van Damme P; van Thiel I; Vandijck D; Vogel W; Waked I; Weis N; Wiegand J; Yosry A; Zekry A; Negro F; Sievert W; Gower E
    J Viral Hepat; 2014 May; 21 Suppl 1():60-89. PubMed ID: 24713006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chronic hepatitis C infection--eradication of the virus].
    Ben Ari Z
    Harefuah; 2014 Jul; 153(7):392-3, 433. PubMed ID: 25189028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shortening HCV therapy: science meets public health.
    Lau G
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):771-772. PubMed ID: 28802817
    [No Abstract]   [Full Text] [Related]  

  • 35. Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis.
    Aspinall EJ; Doyle JS; Corson S; Hellard ME; Hunt D; Goldberg D; Nguyen T; Falck-Ytter Y; Morgan RL; Smith B; Stoove M; Wiktor SZ; Hutchinson S
    Eur J Epidemiol; 2015 Feb; 30(2):115-29. PubMed ID: 25385677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver fibrosis progression in hepatitis C virus infection after seroconversion.
    Butt AA; Yan P; Lo Re V; Rimland D; Goetz MB; Leaf D; Freiberg MS; Klein MB; Justice AC; Sherman KE;
    JAMA Intern Med; 2015 Feb; 175(2):178-85. PubMed ID: 25485735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C.
    McEwan P; Ward T; Bennett H; Kalsekar A; Webster S; Brenner M; Yuan Y
    PLoS One; 2015; 10(1):e0117334. PubMed ID: 25635922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
    Chhatwal J; He T; Lopez-Olivo MA
    Pharmacoeconomics; 2016 Jun; 34(6):551-67. PubMed ID: 26748919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.
    Zoulim F; Liang TJ; Gerbes AL; Aghemo A; Deuffic-Burban S; Dusheiko G; Fried MW; Pol S; Rockstroh JK; Terrault NA; Wiktor S
    Gut; 2015 Nov; 64(11):1824-33. PubMed ID: 26449729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A path to eradication of hepatitis C in low- and middle-income countries.
    Graham CS; Swan T
    Antiviral Res; 2015 Jul; 119():89-96. PubMed ID: 25615583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.